Contract research group hVIVO PLC said its consultancy services division, Venn Life Sciences, has signed a contract with an unnamed "major global pharmaceutical client" worth €3.2mln over two years.
The work will see the Venn team in Breda provide dedicated complex clinical pharmacokinetics (PK) consultancy and programming services to study the absorption, distribution and excretion of drugs within the body.
hVIVO chief executive Mo Khan said: "The consultancy work included in this two-year contract highlights the continued expansion of our pharmacokinetic and programming services as part of Venn's integrated drug development services provision.
“Venn's outstanding expertise and reputation in the industry over the past 25 years makes them a go-to partner.
“In addition, for infectious disease products, hVIVO and Venn have also been able to conduct projects from discovery to phase II challenge studies, something no one else can offer."
Formerly called Open Orphan, hVIVO provides specialist services to the pharma industry, including human challenge studies used to test vaccines along with clinical trial support.